Highlight selection of radiochemistry and developments by board

HIGHLIGHTS

• who: Toyohara et_al EJNMMI Radiopharmacy and collaborators from the The fibroblast activation protein (FAP) has drawn a lot of attention in the last years due to its great promise as a targeting agent for both cancer diagnostics and radionuclide therapyA derivative of FAP, OncoFAP has recently been developed showing improved affinity for malignant tissue (Millul et_al, ). The paper u2018Translational Imaging of the Fibroblast activation protein (FAP) using the new ligand [ Ga]Ga-OncoFAP-DOTAGA highlights the first clinical trials and demonstrate its potential (Backhaus et_al, ). The authors first performed pre-clinical studies in murine tumour models expressing . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.